• Mashup Score: 0

    Linda Kossoff is a medical writer and editor based in Los Angeles. Ruxolitinib treatment resulted in superior complete response (CR), event-free survival (EFS), and molecular response compared with best available therapy (BAT) in patients with polycythemia vera (PV) that is resistant or intolerant to hydroxycarbamide (HC-INT/RES), according to a study published in the Journal of Clinical Oncology. PV is a myeloproliferative neoplasm driven by JAK2 mutations and characterized by erythrocytosis, thromboembol

    Tweet Tweets with this article
    • In patients with #polycythemiavera that is resistant or intolerant to #hydroxycarbamide, treatment with #ruxolitinib was found to achieve superior complete response, event-free survival, and molecular response compared with the best available therapy https://t.co/WUPmBuFqVa

  • Mashup Score: 1

    Anna B. Halpern, MD, discusses key efficacy data from the phase 1/2 MANIFEST trial (NCT02158858) investigating the BET inhibitor pelabresib plus ruxolitinib, and highlights the agents clinical significance in patients with myelofibrosis.

    Tweet Tweets with this article
    • WATCH: Anna B. Halpern, MD, OF @fredhutch, discusses key efficacy data from the phase 1/2 MANIFEST trial investigating the BET inhibitor #pelabresib plus #ruxolitinib, and highlights the agents clinical significance in patients with #myelofibrosis. https://t.co/TUUFxiVxNw